This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mohede DCJ, de Jong IJ, van Driel MF. Medical treatments of Peyronie’s disease: past, present, and future. Urology. 2019;125:1–5.
Tsambarlis P, Levine LA. Nonsurgical management of Peyronie’s disease. Nat Rev Urol. 2019;16:172–86.
Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53.
Sullivan J, Moskovic D, Nelson C, Levine L, Mulhall J. Peyronie’s disease: urologist’s knowledge base and practice patterns. Andrology. 2015;3:260–4.
Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12:E197–e209.
Cowper MG, Burkett CB, Le TV, Scherzer N, Hellstrom WJG. Penile stretching as a treatment for Peyronie’s Disease: a review. Sex Med Rev. 2019;7:508–15.
Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie’s disease: a review. Int J Impot Res. 2002;14:324–8.
Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176:394–8.
Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.
Hoy SM. Collagenase clostridium histolyticum: a review in Peyronie’s disease. Clin Drug Investig. 2020;40:83–92.
Smeraglia F, Del Buono A, Maffulli N. Collagenase clostridium histolyticum in Dupuytren’s contracture: a systematic review. Br Med Bull. 2016;118:149–58.
Sukumar S, Pijush DB, Brandes S. Impact of the advent of collagenase clostridium histolyticum on the surgical management of Peyronie’s disease: a population-based analysis. J Sex Med. 2020;17:111–6.
Yafi FA, Diao L, DeLay KJ, DeYoung L, Talib R, Alzweri L, et al. Multi-institutional prospective analysis of intralesional injection of collagenase clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie’s disease. Urology. 2018;120:138–42.
Barbosa ARG, Takemura LS, Cha JD, Carneiro A, Lemos GC, Glina S, et al. Surgical treatment of Peyronie’s disease: systematic review of techniques involving or not tunica albuginea incision. Sex Med Rev. 2020;8:324–32.
Yang KK, Bennett N. Peyronie’s disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016;94:143–7.
Ziegelmann MJ, Viers BR, Montgomery BD, Westerman ME, Savage JB, Trost LW. Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase clostridium histolyticum injections for Peyronie disease. Urology. 2017;106:107–12.
Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195:1051–6.
Papagiannopoulos D, Yura E, Levine L. Examining postoperative outcomes after employing a surgical algorithm for management of Peyronie’s disease: a single-institution retrospective review. J Sex Med. 2015;12:1474–80.
Yafi FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost LW, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie’s disease. J Urol. 2015;194:754–8.
Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J Sex Med. 2012;9:288–95.
Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie’s disease. J Sex Med. 2019;16:891–900.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
FAY: Coloplast Corporation (consultant, advisory board) and Endo Pharmaceuticals (consultant, advisory board, speaker). MJZ: no pertinent conflicts of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ziegelmann, M.J., Yafi, F.A. Collagenase clostridium histolyticum is no longer available in Europe: what does this mean for our patients with Peyronie’s Disease?. Int J Impot Res 33, 376–377 (2021). https://doi.org/10.1038/s41443-020-0271-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-020-0271-3